Short answer
Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on July 1, 2026 reporting Item 7.01 (Regulation FD Disclosure). Updated corporate presentation reflects Compass Therapeutics’ latest corporate developments.
Compass Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation reflects Compass Therapeutics’ latest corporate developments
- Presentation includes data from the COMPANION-002 clinical study
- Clinical data update may influence investor assessment of program progress and development risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Compass Therapeutics, Inc. 8-K filings
Get the next CMPX 8-K as it lands
Follow CMPX for push alerts, or ask the research agent what this filing means.